Skip to content
Congress Index

119th Congress

Menu

119th Congress

Title 21 — Food and Drugs

Part B · Chapter 9 — Federal Food, Drug, and Cosmetic Act

§ 360ff. Priority review to encourage treatments for rare pediatric diseases

Statutory text

(a)

Definitions

In this section:

(1)

Priority review

The term “priority review”, with respect to a human drug application as defined in section 379g(1) of this title, means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures of the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012.

(2)

Priority review voucher

The term “priority review voucher” means a voucher issued by the Secretary to the sponsor of a rare pediatric disease product application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] after the date of approval of the rare pediatric disease product application.

(3)

Rare pediatric disease

The term “rare pediatric disease” means a disease that meets each of the following criteria:

(A)

The disease is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.

(B)

The disease is a rare disease or condition, within the meaning of section 360bb of this title.

(4)

Rare pediatric disease product application

The term “rare pediatric disease product application” means a human drug application, as defined in section 379g(1) of this title, that—

(A)

is for a drug or biological product that is for the prevention or treatment of a rare pediatric disease;

(B)
(i)

is for such a drug—

(I)

that contains no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) that has been previously approved in any other application under subsection (b)(1), (b)(2), or (j) of section 355 of this title; and

(II)

that is the subject of an application submitted under section 355(b)(1) of this title; or

(ii)

is for such a biological product—

(I)

that contains no active ingredient that has been previously approved in any other application under section 351(a) or 351(k) of the Public Health Service Act [42 U.S.C. 262(a), 262(k)]; and

(II)

that is the subject of an application submitted under section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)];

(C)

the Secretary deems eligible for priority review;

(D)

that 1 relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population;

(E)

that 1 does not seek approval for an adult indication in the original rare pediatric disease product application; and

(F)

is approved after .

(b)

Priority review voucher

(1)

In general

The Secretary shall award a priority review voucher to the sponsor of a rare pediatric disease product application upon approval by the Secretary of such rare pediatric disease product application.

(2)

Transferability

(A)

In general

The sponsor of a rare pediatric disease product application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.

(B)

Notification of transfer

Each person to whom a voucher is transferred shall notify the Secretary of such change in ownership of the voucher not later than 30 days after such transfer.

(3)

Limitation

A sponsor of a rare pediatric disease product application may not receive a priority review voucher under this section if the rare pediatric disease product application was submitted to the Secretary prior to the date that is 90 days after .

(4)

Notification

(A)

Sponsor of a rare pediatric disease product

(i)

In general

Beginning on the date that is 90 days after , the sponsor of a rare pediatric disease product application that intends to request a priority review voucher under this section shall notify the Secretary of such intent upon submission of the rare pediatric disease product application that is the basis of the request for a priority review voucher.

(ii)

Applications submitted but not yet approved

The sponsor of a rare pediatric disease product application that was submitted and that has not been approved as of , shall be considered eligible for a priority review voucher, if—

(I)

such sponsor has submitted such rare pediatric disease product application—

(aa)

on or after the date that is 90 days after ; and

(bb)

on or before ; and

(II)

such application otherwise meets the criteria for a priority review voucher under this section.

(B)

Sponsor of a drug application using a priority review voucher

(i)

In general

The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay the user fee to be assessed in accordance with this section.

(ii)

Transfer after notice

The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under clause (i) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.

(5)

Termination of authority

The Secretary may not award any priority review vouchers under paragraph (1) after .

(c)

Priority review user fee

(1)

In general

The Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under subchapter VII.

(2)

Fee amount

The amount of the priority review user fee shall be determined each fiscal year by the Secretary, based on the difference between—

(A)

the average cost incurred by the Food and Drug Administration in the review of a human drug application subject to priority review in the previous fiscal year; and

(B)

the average cost incurred by the Food and Drug Administration in the review of a human drug application that is not subject to priority review in the previous fiscal year.

(3)

Annual fee setting

The Secretary shall establish, before the beginning of each fiscal year beginning after , the amount of the priority review user fee for that fiscal year.

(4)

Payment

(A)

In general

The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for which the priority review voucher is used. All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.

(B)

Complete application

An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary’s procedures for paying such fees.

(C)

No waivers, exemptions, reductions, or refunds

The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.

(5)

Offsetting collections

Fees collected pursuant to this subsection for any fiscal year—

(A)

shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and

(B)

shall not be collected for any fiscal year except to the extent provided in advance in appropriations Acts.

(d)

Designation process

(1)

In general

Upon the request of the manufacturer or the sponsor of a new drug, the Secretary may designate—

(A)

the new drug as a drug for a rare pediatric disease; and

(B)

the application for the new drug as a rare pediatric disease product application.

(2)

Request for designation

The request for a designation under paragraph (1) shall be made at the same time a request for designation of orphan disease status under section 360bb of this title or fast-track designation under section 356 of this title is made. Requesting designation under this subsection is not a prerequisite to receiving a priority review voucher under this section.

(3)

Determination by Secretary

Not later than 60 days after a request is submitted under paragraph (1), the Secretary shall determine whether—

(A)

the disease or condition that is the subject of such request is a rare pediatric disease; and

(B)

the application for the new drug is a rare pediatric disease product application.

(e)

Marketing of rare pediatric disease products

(1)

Revocation

The Secretary may revoke any priority review voucher awarded under subsection (b) if the rare pediatric disease product for which such voucher was awarded is not marketed in the United States within the 365-day period beginning on the date of the approval of such drug under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262].

(2)

Postapproval production report

The sponsor of an approved rare pediatric disease product shall submit a report to the Secretary not later than 5 years after the approval of the applicable rare pediatric disease product application. Such report shall provide the following information, with respect to each of the first 4 years after approval of such product:

(A)

The estimated population in the United States suffering from the rare pediatric disease.

(B)

The estimated demand in the United States for such rare pediatric disease product.

(C)

The actual amount of such rare pediatric disease product distributed in the United States.

(f)

Notice and report

(1)

Notice of issuance of voucher and approval of products under voucher

The Secretary shall publish a notice in the Federal Register and on the Internet Web site of the Food and Drug Administration not later than 30 days after the occurrence of each of the following:

(A)

The Secretary issues a priority review voucher under this section.

(B)

The Secretary approves a drug pursuant to an application submitted under section 355(b) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for which the sponsor of the application used a priority review voucher under this section.

(2)

Notification

If, after the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section, a sponsor of an application submitted under section 355(b) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] for a drug uses a priority review voucher under this section for such application, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a document—

(A)

notifying such Committees of the use of such voucher; and

(B)

identifying the drug for which such priority review voucher is used.

(g)

Eligibility for other programs

Nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this chapter, except that no sponsor of a rare pediatric disease product application may receive more than one priority review voucher issued under any section of this chapter with respect to the drug for which the application is made..3

(h)

Relation to other provisions

The provisions of this section shall supplement, not supplant, any other provisions of this chapter or the Public Health Service Act [42 U.S.C. 201 et seq.] that encourage the development of drugs for tropical diseases and rare pediatric diseases.

(i)

GAO study and report

(1)

Study

(A)

In general

Beginning on the date that the Secretary awards the third rare pediatric disease priority voucher under this section, the Comptroller General of the United States shall conduct a study of the effectiveness of awarding rare pediatric disease priority vouchers under this section in the development of human drug products that treat or prevent such diseases.

(B)

Contents of study

In conducting the study under subparagraph (A), the Comptroller General shall examine the following:

(i)

The indications for which each rare disease product for which a priority review voucher was awarded was approved under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262].

(ii)

Whether, and to what extent, an unmet need related to the treatment or prevention of a rare pediatric disease was met through the approval of such a rare disease product.

(iii)

The value of the priority review voucher if transferred.

(iv)

Identification of each drug for which a priority review voucher was used.

(v)

The length of the period of time between the date on which a priority review voucher was awarded and the date on which it was used.

(2)

Report

Not later than 1 year after the date under paragraph (1)(A), the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, a report containing the results of the study under paragraph (1).

Footnotes

  1. 1 So in original. The word “that” probably should not appear.
  2. 3 So in original.

Legislative history

Reconstructed from this section’s Code source credit and amendment notes, resolved against the local Statutes at Large. Editorial notes are evidence, not the law that made the change.

  1. Food and Drug Administration Safety and Innovation Act

    Pub. L. 112–144 title IX § 908 · 126 Stat. 993

    Enacted · 21 U.S.C. § 360ff

    June 25, 1938, ch. 675, § 529, as added Pub. L. 112–144, title IX, § 908, July 9, 2012, 126 Stat. 1094

    Source evidence

    Code source credit
    June 25, 1938, ch. 675, § 529, as added Pub. L. 112–144, title IX, § 908, July 9, 2012, 126 Stat. 1094

    Enacted provision · exact public law section
    SEC. 908. RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER INCENTIVE PROGRAM.   Subchapter B of chapter V (21 U.S.C. 360aa et seq.) is amended by adding at the end the following: “SEC. 529. PRIORITY REVIEW TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES. “(a) Definitions.— In this section: “(1) Priority review.— The term ‘priority review’, with respect to a human drug application as defined in section 735(1), means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures of the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012. “(2) Priority review voucher.— The term ‘priority review voucher’ means a voucher issued by the Secretary to the sponsor of a rare pediatric disease product application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 505(b)(1) or section 351(a) of the Public Health Service Act after the date of approval of the rare pediatric disease product application. “(3) Rare pediatric disease.— The term ‘rare pediatric disease’ means a disease that meets each of the following criteria: “(A) The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents. “(B) The disease is a rare disease or condition, within the meaning of section 526. “(4) Rare pediatric disease product application.— The term ‘rare pediatric disease product application’ means a human drug application, as defined in section 735(1), that— “(A) is for a drug or biological product— “(i) that is for the prevention or treatment of a rare pediatric disease; and “(ii) that contains no active ingredient (including any ester or salt of the active ingredient) that has been previously approved in any other application under section 505(b)(1), 505(b)(2), or 505(j) of this Act or section 351(a) or 351(k) of the Public Health Service Act; “(B) is submitted under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act; “(C) the Secretary deems eligible for priority review; “(D) that relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population; “(E) that does not seek approval for an adult indication in the original rare pediatric disease product application; and “(F) is approved after the date of the enactment of the Prescription Drug User Fee Amendments of 2012. “(b) Priority Review Voucher.— “(1) In general.— The Secretary shall award a priority review voucher to the sponsor of a rare pediatric disease product application upon approval by the Secretary of such rare pediatric disease product application. “(2) Transferability.— “(A) In general.— The sponsor of a rare pediatric disease product application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used. “(B) Notification of transfer.— Each person to whom a voucher is transferred shall notify the Secretary of such change in ownership of the voucher not later than 30 days after such transfer. “(3) Limitation.— A sponsor of a rare pediatric disease product application may not receive a priority review voucher under this section if the rare pediatric disease product application was submitted to the Secretary prior to the date that is 90 days after the date of enactment of the Prescription Drug User Fee Amendments of 2012. “(4) Notification.— “(A) In general.— The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section. “(B) Transfer after notice.— The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph (A) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification. “(5) Termination of authority.— The Secretary may not award any priority review vouchers under paragraph (1) after the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section. “(c) Priority Review User Fee.— “(1) In general.— The Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under chapter VII. “(2) Fee amount.— The amount of the priority review user fee shall be determined each fiscal year by the Secretary, based on the difference between— “(A) the average cost incurred by the Food and Drug Administration in the review of a human drug application subject to priority review in the previous fiscal year; and “(B) the average cost incurred by the Food and Drug Administration in the review of a human drug application that is not subject to priority review in the previous fiscal year. “(3) Annual fee setting.— The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2012, the amount of the priority review user fee for that fiscal year. “(4) Payment.— “(A) In general.— The priority review user fee required by this subsection shall be due upon the notification by a sponsor of the intent of such sponsor to use the voucher, as specified in subsection (b)(4)(A). All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law. “(B) Complete application.— An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary’s procedures for paying such fees. “(C) No waivers, exemptions, reductions, or refunds.— The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section. “(5) Offsetting collections.— Fees collected pursuant to this subsection for any fiscal year— “(A) shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and “(B) shall not be collected for any fiscal year except to the extent provided in advance in appropriations Acts. “(d) Designation Process.— “(1) In general.— Upon the request of the manufacturer or the sponsor of a new drug, the Secretary may designate— “(A) the new drug as a drug for a rare pediatric disease; and “(B) the application for the new drug as a rare pediatric disease product application. “(2) Request for designation.— The request for a designation under paragraph (1) shall be made at the same time a request for designation of orphan disease status under section 526 or fast-track designation under section 506 is made. Requesting designation under this subsection is not a prerequisite to receiving a priority review voucher under this section. “(3) Determination by secretary.— Not later than 60 days after a request is submitted under paragraph (1), the Secretary shall determine whether— “(A) the disease or condition that is the subject of such request is a rare pediatric disease; and “(B) the application for the new drug is a rare pediatric disease product application. “(e) Marketing of Rare Pediatric Disease Products.— “(1) Revocation.— The Secretary may revoke any priority review voucher awarded under subsection (b) if the rare pediatric disease product for which such voucher was awarded is not marketed in the United States within the 365-day period beginning on the date of the approval of such drug under section 505 of this Act or section 351 of the Public Health Service Act. “(2) Postapproval production report.— The sponsor of an approved rare pediatric disease product shall submit a report to the Secretary not later than 5 years after the approval of the applicable rare pediatric disease product application. Such report shall provide the following information, with respect to each of the first 4 years after approval of such product: “(A) The estimated population in the United States suffering from the rare pediatric disease. “(B) The estimated demand in the United States for such rare pediatric disease product. “(C) The actual amount of such rare pediatric disease product distributed in the United States. “(f) Notice and Report.— “(1) Notice of issuance of voucher and approval of products under voucher.— The Secretary shall publish a notice in the Federal Register and on the Internet Web site of the Food and Drug Administration not later than 30 days after the occurrence of each of the following: “(A) The Secretary issues a priority review voucher under this section. “(B) The Secretary approves a drug pursuant to an application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for which the sponsor of the application used a priority review voucher under this section. “(2) Notification.— If, after the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section, a sponsor of an application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for a drug uses a priority review voucher under this section for such application, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a document— “(A) notifying such Committees of the use of such voucher; and “(B) identifying the drug for which such priority review voucher is used. “(g) Eligibility for Other Programs.— Nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this Act. “(h) Relation to Other Provisions.— The provisions of this section shall supplement, not supplant, any other provisions of this Act or the Public Health Service Act that encourage the development of drugs for tropical diseases and rare pediatric diseases. “(i) GAO Study and Report.— “(1) Study.— “(A) In general.— Beginning on the date that the Secretary awards the third rare pediatric disease priority voucher under this section, the Comptroller General of the United States shall conduct a study of the effectiveness of awarding rare pediatric disease priority vouchers under this section in the development of human drug products that treat or prevent such diseases. “(B) Contents of study.— In conducting the study under subparagraph (A), the Comptroller General shall examine the following: “(i) The indications for which each rare disease product for which a priority review voucher was awarded was approved under section 505 or section 351 of the Public Health Service Act. “(ii) Whether, and to what extent, an unmet need related to the treatment or prevention of a rare pediatric disease was met through the approval of such a rare disease product. “(iii) The value of the priority review voucher if transferred. “(iv) Identification of each drug for which a priority review voucher was used. “(v) The length of the period of time between the date on which a priority review voucher was awarded and the date on which it was used. “(2) Report.— Not later than 1 year after the date under paragraph (1)(A), the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, a report containing the results of the study under paragraph (1).” .

  2. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016

    Pub. L. 114–113 div. A title VII § 765 · 129 Stat. 2242

    Substituted · 21 U.S.C. § 360ff(b)(5)

    Pub. L. 114–113 substituted “September 30, 2016.” for “the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section.”

    Source evidence

    Code amendment note
    Subsec. (b)(5). Pub. L. 114–113 substituted “September 30, 2016.” for “the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section.”

    Enacted provision · exact public law section
    Sec. 765. Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)(5)) is amended by striking “the last day” and all that follows through the period at the end and inserting “September 30, 2016.”.

  3. Advancing Hope Act of 2016

    Pub. L. 114–229 § 2(a)(1)(A) · 130 Stat. 943

    Amended · 21 U.S.C. § 360ff(a)(3)(A)

    Pub. L. 114–229, § 2(a)(1)(A), amended subpar. (A) generally. Prior to amendment, subpar. (A) read as follows: “The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.”

    Source evidence

    Code amendment note
    Subsec. (a)(3)(A). Pub. L. 114–229, § 2(a)(1)(A), amended subpar. (A) generally. Prior to amendment, subpar. (A) read as follows: “The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.”

    Enacted provision · exact public law section
    (A) in paragraph (3), by amending subparagraph (A) to read as follows: “(A) The disease is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.” ; and

  4. Advancing Hope Act of 2016

    Pub. L. 114–229 § 2(a)(1)(B) · 130 Stat. 943

    Substituted · 21 U.S.C. § 360ff(a)(4)(F)

    Pub. L. 114–229, § 2(a)(1)(B), substituted “September 30, 2016” for “July 9, 2012”

    Source evidence

    Code amendment note
    Subsec. (a)(4)(F). Pub. L. 114–229, § 2(a)(1)(B), substituted “September 30, 2016” for “July 9, 2012”.

    Enacted provision · exact public law section
    (B) in paragraph (4)(F), by striking “Prescription Drug User Fee Amendments of 2012” and inserting “Advancing Hope Act of 2016”;

  5. Advancing Hope Act of 2016

    Pub. L. 114–229 § 2(a)(2)(A) · 130 Stat. 943

    1. Added · 21 U.S.C. § 360ff(b)(4)

      Pub. L. 114–229, § 2(a)(2)(A), added par. (4)

    2. Struck · 21 U.S.C. § 360ff(b)(4)

      Pub. L. 114–229, § 2(a)(2)(A), struck out former par. (4). Prior to amendment, text read as follows:

    Source evidence

    Code amendment note
    Subsec. (b)(4). Pub. L. 114–229, § 2(a)(2)(A), added par. (4) and struck out former par. (4). Prior to amendment, text read as follows:

    “(A) In general.—The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section. “(B) Transfer after notice.—The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph (A) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.”

    Enacted provision · exact public law section
    (A) by striking paragraph (4) and inserting the following: “(4) Notification.— “(A) Sponsor of a rare pediatric disease product.— “(i) In general.— Beginning on the date that is 90 days after the date of enactment of the Advancing Hope Act of 2016, the sponsor of a rare pediatric disease product application that intends to request a priority review voucher under this section shall notify the Secretary of such intent upon submission of the rare pediatric disease product application that is the basis of the request for a priority review voucher. “(ii) Applications submitted but not yet approved.— The sponsor of a rare pediatric disease product application that was submitted and that has not been approved as of the date of enactment of the Advancing Hope Act of 2016 shall be considered eligible for a priority review voucher, if— “(I) such sponsor has submitted such rare pediatric disease product application— “(aa) Time period. on or after the date that is 90 days after the date of enactment of the Prescription Drug User Fee Amendments of 2012; and “(bb) on or before the date of enactment of the Advancing Hope Act of 2016; and “(II) such application otherwise meets the criteria for a priority review voucher under this section. “(B) Sponsor of a drug application using a priority review voucher.— “(i) In general.— The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay the user fee to be assessed in accordance with this section. “(ii) Transfer after notice.— The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under clause (i) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.” ; and

  6. Advancing Hope Act of 2016

    Pub. L. 114–229 § 2(a)(2)(B) · 130 Stat. 943

    1. Added · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 114–229, § 2(a)(2)(B), added par. (5)

    2. Struck · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 114–229, § 2(a)(2)(B), struck out former par. (5). Prior to amendment, text read as follows: “The Secretary may not award any priority review vouchers under paragraph (1) after September 30, 2016.”

    Target inherited from the preceding amendment note.

    Source evidence

    Code amendment note
    Pub. L. 114–229, § 2(a)(2)(B), added par. (5) and struck out former par. (5). Prior to amendment, text read as follows: “The Secretary may not award any priority review vouchers under paragraph (1) after September 30, 2016.”

    Enacted provision · exact public law section
    (B) by striking paragraph (5) and inserting the following: “(5) Termination of authority.— The Secretary may not award any priority review vouchers under paragraph (1) after December 31, 2016.” ; and

  7. Advancing Hope Act of 2016

    Pub. L. 114–229 § 2(a)(3) · 130 Stat. 943

    Inserted · 21 U.S.C. § 360ff(g)

    Pub. L. 114–229, § 2(a)(3), inserted before period at end “, except that no sponsor of a rare pediatric disease product application may receive more than one priority review voucher issued under any section of this chapter with respect to the drug for which the application is made.”

    Source evidence

    Code amendment note
    Subsec. (g). Pub. L. 114–229, § 2(a)(3), inserted before period at end “, except that no sponsor of a rare pediatric disease product application may receive more than one priority review voucher issued under any section of this chapter with respect to the drug for which the application is made.”

    Enacted provision · exact public law section
    (3) in subsection (g), by inserting before the period “, except that no sponsor of a rare pediatric disease product application may receive more than one priority review voucher issued under any section of this Act with respect to the drug for which the application is made.”

  8. 21st Century Cures Act

    Pub. L. 114–255 div. A title III § 3013(a) · 130 Stat. 1033

    1. Added · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 114–255 added par. (5)

    2. Struck · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 114–255 struck out former par. (5). Prior to amendment, text read as follows: “The Secretary may not award any priority review vouchers under paragraph (1) after December 31, 2016.”

    Source evidence

    Code amendment note
    Subsec. (b)(5). Pub. L. 114–255 added par. (5) and struck out former par. (5). Prior to amendment, text read as follows: “The Secretary may not award any priority review vouchers under paragraph (1) after December 31, 2016.”

    Enacted provision · exact public law section
    (a) In General.— Section 529(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)) is amended by striking paragraph (5) and inserting the following: “(5) Termination of authority.— The Secretary may not award any priority review vouchers under paragraph (1) after September 30, 2020, unless the rare pediatric disease product application— “(A) is for a drug that, not later than September 30, 2020, is designated under subsection (d) as a drug for a rare pediatric disease; and “(B) is, not later than September 30, 2022, approved under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act.” .

  9. Continuing Appropriations Act, 2021 and Other Extensions Act

    Pub. L. 116–159 div. C title I § 2105 · 134 Stat. 709

    1. Substituted · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 116–159 substituted “December 11, 2020” for “September 30, 2020” in introductory provisions and in subpar. (A)

    2. Substituted · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 116–159 substituted “December 11, 2022” for “September 30, 2022” in subpar. (B)

    Target inherited from the preceding amendment note.

    Source evidence

    Code amendment note
    Pub. L. 116–159 substituted “December 11, 2020” for “September 30, 2020” in introductory provisions and in subpar. (A) and substituted “December 11, 2022” for “September 30, 2022” in subpar. (B).

    Enacted provision · exact public law section
    SEC. 2105. RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER EXTENSION.   Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)(5)) is amended— (1) by striking “September 30, 2020” each place it appears and inserting “December 11, 2020”; and (2) in subparagraph (B), by striking “September 30, 2022” and inserting “December 11, 2022”.

  10. Further Continuing Appropriations Act, 2021, and Other Extensions Act

    Pub. L. 116–215 div. B title II § 1211 · 134 Stat. 1041

    1. Substituted · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 116–215 substituted “December 18, 2020” for “December 11, 2020” in introductory provisions and in subpar. (A)

    2. Substituted · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 116–215 substituted “December 18, 2022” for “December 11, 2022” in subpar. (B)

    Target inherited from the preceding amendment note.

    Source evidence

    Code amendment note
    Pub. L. 116–215 substituted “December 18, 2020” for “December 11, 2020” in introductory provisions and in subpar. (A) and substituted “December 18, 2022” for “December 11, 2022” in subpar. (B).

    Enacted provision · exact public law section
    SEC. 1211. RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER EXTENSION.   Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)(5)) is amended— (1) by striking “December 11, 2020” each place it appears and inserting “December 18, 2020”; and (2) in subparagraph (B), by striking “December 11, 2022” and inserting “December 18, 2022”.

  11. Coronavirus Response and Relief Supplemental Appropriations Act, 2021

    Pub. L. 116–260 div. BB title III § 321 · 134 Stat. 1182

    1. Substituted · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 116–260 substituted “September 30, 2024” for “December 18, 2020” in introductory provisions and in subpar. (A)

    2. Substituted · 21 U.S.C. § 360ff(b)(5)

      Pub. L. 116–260 substituted “September 30, 2026” for “December 18, 2022” in subpar. (B)

    Source evidence

    Code amendment note
    Subsec. (b)(5). Pub. L. 116–260 substituted “September 30, 2024” for “December 18, 2020” in introductory provisions and in subpar. (A) and substituted “September 30, 2026” for “December 18, 2022” in subpar. (B).

    Enacted provision · exact public law section
    Sec. 321. Not later than 30 days after the date of enactment of this Act, the Secretaries of Health and Human Services and Education shall provide a detailed spend plan of anticipated uses of funds made available in this title, including estimated personnel and administrative costs, to the Committees on Appropriations of the House of Representatives and the Senate: Provided, Time period. That such plans shall be updated and submitted to such Committees every 60 days until September 30, 2024: Provided further, List. Contracts. That the spend plans shall be accompanied by a listing of each contract obligation incurred that exceeds $5,000,000 which has not previously been reported, including the amount of each such obligation.

  12. Pub. L. 117–9 § 1(a)(4) · 135 Stat. 255

    1. Added · 21 U.S.C. § 360ff(a)(4)(A); 21 U.S.C. § 360ff(a)(4)(B)

      Pub. L. 117–9 added subpars. (A) and (B)

    2. Struck · 21 U.S.C. § 360ff(a)(4)(A); 21 U.S.C. § 360ff(a)(4)(B)

      Pub. L. 117–9 struck out former subpars. (A) and (B) which read as follows:

    Source evidence

    Code amendment note
    Subsec. (a)(4)(A), (B). Pub. L. 117–9 added subpars. (A) and (B) and struck out former subpars. (A) and (B) which read as follows:

    “(A) is for a drug or biological product— “(i) that is for the prevention or treatment of a rare pediatric disease; and “(ii) that contains no active ingredient (including any ester or salt of the active ingredient) that has been previously approved in any other application under section 355(b)(1), 355(b)(2), or 355(j) of this title or section 351(a) or 351(k) of the Public Health Service Act; “(B) is submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act;”.

    Enacted provision · exact public law section
    (4) in section 529(a)(4) (21 U.S.C. 360ff(a)(4)), by striking subparagraphs (A) and (B) and inserting the following: “(A) is for a drug or biological product that is for the prevention or treatment of a rare pediatric disease; “(B) (i) is for such a drug— “(I) that contains no active moiety (as defined by the Secretary in section 314.3 of title 21, Code of Federal Regulations (or any successor regulations)) that has been previously approved in any other application under subsection (b)(1), (b)(2), or (j) of section 505; and “(II) that is the subject of an application submitted under section 505(b)(1); or “(ii) is for such a biological product— “(I) that contains no active ingredient that has been previously approved in any other application under section 351(a) or 351(k) of the Public Health Service Act; and “(II) that is the subject of an application submitted under section 351(a) of the Public Health Service Act;” ; and

  13. Pub. L. 118–83 div. B title II § 202 · 138 Stat. 1538

    Substituted · 21 U.S.C. § 360ff(b)(5)

    Pub. L. 118–83 substituted “December 20, 2024” for “September 30, 2024” in introductory provisions and in subpar. (A)

    Unresolved: Pub. L. 118–83 was not found in the local Statutes at Large index.

    Source evidence

    Code amendment note
    Subsec. (b)(5). Pub. L. 118–83 substituted “December 20, 2024” for “September 30, 2024” in introductory provisions and in subpar. (A).

  14. Pub. L. 119–75 § 6604(a) · 140 Stat. 699

    Substituted · 21 U.S.C. § 360ff(b)

    Pub. L. 119–75, § 6604(a), substituted “September 30, 2029.” for “December 20, 2024, unless the rare pediatric disease product application—

    Unresolved: Pub. L. 119–75 was not found in the local Statutes at Large index.

    Source evidence

    Code amendment note
    Subsec. (b). Pub. L. 119–75, § 6604(a), substituted “September 30, 2029.” for “December 20, 2024, unless the rare pediatric disease product application—

    “(A) is for a drug that, not later than December 20, 2024, is designated under subsection (d) as a drug for a rare pediatric disease; and “(B) is, not later than September 30, 2026, approved under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act.”

  15. Pub. L. 119–75 § 6604(b) · 140 Stat. 699

    1. Added · 21 U.S.C. § 360ff(c)(4)(A)

      Pub. L. 119–75, § 6604(b), added subpar. (A)

    2. Struck · 21 U.S.C. § 360ff(c)(4)(A)

      Pub. L. 119–75, § 6604(b), struck out former subpar. (A). Prior to amendment, text read as follows: “The priority review user fee required by this subsection shall be due upon the notification by a sponsor of the intent of such sponsor to use the voucher, as specified in subsection (b)(4)(A). All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.”

    Unresolved: Pub. L. 119–75 was not found in the local Statutes at Large index.

    Source evidence

    Code amendment note
    Subsec. (c)(4)(A). Pub. L. 119–75, § 6604(b), added subpar. (A) and struck out former subpar. (A). Prior to amendment, text read as follows: “The priority review user fee required by this subsection shall be due upon the notification by a sponsor of the intent of such sponsor to use the voucher, as specified in subsection (b)(4)(A). All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.”

19 of 23 references resolved to an enrolled provision · 4 unresolved

Editorial Notes

References in Text

Section 101(b) of the Prescription Drug User Fee Amendments of 2012, referred to in subsec. (a)(1), is section 101(b) of Pub. L. 112–144, which is set out as a note under section 379g of this title.

The Public Health Service Act, referred to in subsec. (h), is act July 1, 1944, ch. 373, 58 Stat. 682, which is classified generally to chapter 6A (§ 201 et seq.) of Title 42, The Public Health and Welfare. For complete classification of this Act to the Code, see Short Title note set out under section 201 of Title 42 and Tables.

Amendments2015–2026 · 6 rounds

2026

Subsec. (b). Pub. L. 119–75, § 6604(a), substituted “.” for “, unless the rare pediatric disease product application—

“(A) is for a drug that, not later than , is designated under subsection (d) as a drug for a rare pediatric disease; and

“(B) is, not later than , approved under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act.”

Subsec. (c)(4)(A). Pub. L. 119–75, § 6604(b), added subpar. (A) and struck out former subpar. (A). Prior to amendment, text read as follows: “The priority review user fee required by this subsection shall be due upon the notification by a sponsor of the intent of such sponsor to use the voucher, as specified in subsection (b)(4)(A). All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.”

2024

Subsec. (b)(5). Pub. L. 118–83 substituted “” for “” in introductory provisions and in subpar. (A).

2021

Subsec. (a)(4)(A), (B). Pub. L. 117–9 added subpars. (A) and (B) and struck out former subpars. (A) and (B) which read as follows:

“(A) is for a drug or biological product—

“(i) that is for the prevention or treatment of a rare pediatric disease; and

“(ii) that contains no active ingredient (including any ester or salt of the active ingredient) that has been previously approved in any other application under section 355(b)(1), 355(b)(2), or 355(j) of this title or section 351(a) or 351(k) of the Public Health Service Act;

“(B) is submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act;”.

2020

Subsec. (b)(5). Pub. L. 116–260 substituted “” for “” in introductory provisions and in subpar. (A) and substituted “” for “” in subpar. (B).

Pub. L. 116–215 substituted “” for “” in introductory provisions and in subpar. (A) and substituted “” for “” in subpar. (B).

Pub. L. 116–159 substituted “” for “” in introductory provisions and in subpar. (A) and substituted “” for “” in subpar. (B).

2016

Subsec. (a)(3)(A). Pub. L. 114–229, § 2(a)(1)(A), amended subpar. (A) generally. Prior to amendment, subpar. (A) read as follows: “The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.”

Subsec. (a)(4)(F). Pub. L. 114–229, § 2(a)(1)(B), substituted “” for “”.

Subsec. (b)(4). Pub. L. 114–229, § 2(a)(2)(A), added par. (4) and struck out former par. (4). Prior to amendment, text read as follows:

“(A) In general.—The sponsor of a human drug application shall notify the Secretary not later than 90 days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section.

“(B) Transfer after notice.—The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph (A) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.”

Subsec. (b)(5). Pub. L. 114–255 added par. (5) and struck out former par. (5). Prior to amendment, text read as follows: “The Secretary may not award any priority review vouchers under paragraph (1) after .”

Pub. L. 114–229, § 2(a)(2)(B), added par. (5) and struck out former par. (5). Prior to amendment, text read as follows: “The Secretary may not award any priority review vouchers under paragraph (1) after .”

Subsec. (g). Pub. L. 114–229, § 2(a)(3), inserted before period at end “, except that no sponsor of a rare pediatric disease product application may receive more than one priority review voucher issued under any section of this chapter with respect to the drug for which the application is made.”

2015

Subsec. (b)(5). Pub. L. 114–113 substituted “.” for “the last day of the 1-year period that begins on the date that the Secretary awards the third rare pediatric disease priority voucher under this section.”

Statutory Notes and Related Subsidiaries

Construction

Pub. L. 114–229, § 2(b), , 130 Stat. 944, provided that: “Nothing in this Act [amending this section and enacting provisions set out as a note under section 301 of this title], or the amendments made by this Act, shall be construed to affect the validity of a priority review voucher that was issued under section 529 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff) before the date of enactment of this Act [].”

Credits

1938–2026 · 10 acts
  1. 1938June 25, 1938, ch. 675, § 529, as added Pub. L. 112–144, title IX, § 908, , 126 Stat. 1094
  2. 2015amended Pub. L. 114–113, div. A, title VII, § 765, , 129 Stat. 2286
  3. 2016Pub. L. 114–229, § 2(a), , 130 Stat. 943
  4. 2016Pub. L. 114–255, div. A, title III, § 3013(a), , 130 Stat. 1093
  5. 2020Pub. L. 116–159, div. C, title I, § 2105, , 134 Stat. 729
  6. 2020Pub. L. 116–215, div. B, title II, § 1211, , 134 Stat. 1045
  7. 2020Pub. L. 116–260, div. BB, title III, § 321, , 134 Stat. 2932
  8. 2021Pub. L. 117–9, § 1(a)(4), , 135 Stat. 257
  9. 2024Pub. L. 118–83, div. B, title II, § 202, , 138 Stat. 1538
  10. 2026Pub. L. 119–75, div. J, title VI, § 6604(a), (b), , 140 Stat. 699.
Show as published

(June 25, 1938, ch. 675, § 529, as added Pub. L. 112–144, title IX, § 908, , 126 Stat. 1094; amended Pub. L. 114–113, div. A, title VII, § 765, , 129 Stat. 2286; Pub. L. 114–229, § 2(a), , 130 Stat. 943; Pub. L. 114–255, div. A, title III, § 3013(a), , 130 Stat. 1093; Pub. L. 116–159, div. C, title I, § 2105, , 134 Stat. 729; Pub. L. 116–215, div. B, title II, § 1211, , 134 Stat. 1045; Pub. L. 116–260, div. BB, title III, § 321, , 134 Stat. 2932; Pub. L. 117–9, § 1(a)(4), , 135 Stat. 257; Pub. L. 118–83, div. B, title II, § 202, , 138 Stat. 1538; Pub. L. 119–75, div. J, title VI, § 6604(a), (b), , 140 Stat. 699.)

Parsed from the official OLRC USLM XML in data/usc_all/usc21.xml · release point 119-108 · OLRC build 2026-04-17

USLM identifier /us/usc/t21/s360ff